Article
Gastroenterology & Hepatology
Gilles Boschetti, Maria Nachury, David Laharie, Xavier Roblin, Cyrielle Gilletta, Alexandre Aubourg, Arnaud Bourreille, Camille Zallot, Xavier Hebuterne, Anthony Buisson, Jean-Charles Grimaud, Yoram Bouhnik, Matthieu Allez, Romain Altwegg, Stephanie Viennot, Lucine Vuitton, Franck Carbonnel, Stephane Paul, Kristell Desseaux, Jerome Lambert, Laurent Peyrin-Biroulet
Summary: This study aimed to investigate the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after discontinuation due to loss of response or intolerance. The results showed that IFX retreatment was effective and safe in approximately one-third of patients with CD, regardless of the reason for prior discontinuation. Early detection of anti-drug antibodies could predict subsequent failure of IFX reintroduction and infusion reactions.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian
Summary: This study compared the efficacy of infliximab (IFX) and adalimumab (ADA) in healing CD-PAF. The results showed that the IFX group had better clinical response at 6 months and higher biologic persistence. In addition, the study supported the use of concomitant immunomodulator therapy for CD-PAF healing and remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Laura H. Bukkems, Krisztina B. Gecse, Geert R. D'Haens, Ron A. A. Mathot
Summary: The study characterized the pharmacokinetics of subcutaneous CT-P13 through population PK modeling, identifying body weight, presence of anti-drug antibodies, and serum albumin concentration as clinically relevant covariates affecting drug clearance. Simulated drug exposure demonstrated differences between routes of administration in patients of varying body weights.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Immunology
Shin Ju Oh, Young Nam Kwon, Chang Kyun Lee, Jin San Lee
Summary: This is the first report of infliximab-associated anti-NMDAR encephalitis in Crohn's disease, highlighting the need for clinicians to recognize the possibility of a paradoxical autoimmune response occurring with novel biological therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Jiri Bronsky, Ivana Copova, Denis Kazeka, Tereza Lerchova, Katarina Mitrova, Kristyna Pospisilova, Miroslava Sulovcova, Kristyna Zarubova, Ondrej Hradsky
Summary: This study compared the efficacy and safety of two anti-tumor necrosis factor therapies (ADA and IFX) in pediatric patients with luminal CD. The results showed no significant differences between ADA and IFX in terms of treatment escalation time, primary nonresponse, or serious adverse events. The combination of anti-S. cerevisiae antibody negativity and antineutrophil cytoplasmic antibody positivity was identified as a strong predictor of treatment escalation.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2022)
Article
Pharmacology & Pharmacy
Xuan Shi, Jia-Hui Wang, Sheng-Xiang Rao, Tao-Tao Liu, Hao Wu
Summary: This study retrospectively analyzed patients with Crohn's disease who received infliximab (IFX) treatment and found that responders to IFX had a decreased splenic volume, while non-responders had an increased splenic volume. The splenic volume was positively correlated with disease activity, indicating its potential as an indicator for evaluating treatment efficacy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Qianqian Li, Xiao Ding, Yujie Liu, Cicilia Marcella, Min Dai, Ting Zhang, Jianling Bai, Liyuan Xiang, Quan Wen, Bota Cui, Faming Zhang
Summary: The study found that FMT could be a switch therapy for patients with prior IFX failure in CD, with gender of donor possibly being an independent predictor of efficacy at one year after FMT. No serious adverse events were observed with FMT, suggesting it to be a safe alternative treatment option.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch
Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe, Mi-Jin Kim
Summary: This study compared the efficacy and immunogenicity of methotrexate (MTX) and azathioprine (AZA) as concurrent therapies for pediatric Crohn's disease (CD). The results showed that there were no significant differences in remission rates between the two medications, and they both effectively maintained adequate Infliximab (IFX) levels and reduced anti-drug antibody (ADA) production.
Article
Pharmacology & Pharmacy
Kouzhu Zhu, Xiaoliang Ding, Zhiyao Chen, Qinhua Xi, Xueqin Pang, Weichang Chen, Liyan Miao
Summary: This study identifies the genetic variants rs2097432 in HLA-DQA1*05 and rs396991 in FCGR3A to be associated with the production of ATI in Chinese patients with CD. These findings have significant implications for the clinical management of CD.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Gastroenterology & Hepatology
Eun Sil Kim, Ben Kang
Summary: The selection of biologic agents for pediatric Crohn's disease should be done carefully, as currently only infliximab and adalimumab are approved for use in children. Lack of comparison trials in pediatric patients necessitates the extrapolation of adult data. From a pharmacokinetic perspective, infliximab may be more advantageous in high inflammatory burden, while adalimumab may be better in sustaining remission during maintenance phase. Factors such as clinical indications, disease behavior, efficacy, safety, immunogenicity, patient preference, and compliance should be considered when choosing anti-TNF therapy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Adam S. Cheifetz, Niels Vande Casteele, Zhongya Wang, Marla C. Dubinsky, Konstantinos Papamichael
Summary: The study found that infliximab concentrations during induction therapy and early after were associated with clinical outcomes in pediatric patients with Crohn's disease. Higher concentrations were associated with better outcomes, indicating the need for tailored dosing to achieve higher exposure to infliximab for better results in this population.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Pediatrics
Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
Summary: This article reports a rare case of a 16-year-old female with Crohn's disease who developed tuberculosis spondylitis during treatment with infliximab. Despite receiving sufficient treatment at each stage of tuberculosis development, tuberculosis spondylitis still occurred.
FRONTIERS IN PEDIATRICS
(2022)
Article
Gastroenterology & Hepatology
Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A. Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig
Summary: This study aimed to compare the relapse rate and time in remission over 2 years between patients continuing combination therapy, stopping infliximab, or stopping immunosuppressant therapy for Crohn's disease. The results showed that stopping infliximab had a higher relapse rate compared to stopping immunosuppressant therapy, suggesting that stopping immunosuppressant therapy may be a preferable strategy for treatment de-escalation.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Luisa Leite Barros, Jane Oba, Carlos Walter Sobrado Junior, Aytan Miranda Sipahi, Olivia Duarte de Castro Alves, Tomas Navarro-Rodriguez, Rogerio Serafim Parra, Julio Maria Fonseca Chebli, Liliana Andrade Chebli, Cristina Flores, Andrea Vieira, Christianne Damasceno Arcelino do Ceara, Natalia Sousa Freitas Queiroz, Aderson Omar Mourao Cintra Damiao
Summary: Therapeutic drug monitoring (TDM) is important in optimizing response to anti-tumor necrosis factor drugs and preventing inadequate drug exposure. This study aimed to describe the remission rates of Brazilian inflammatory bowel disease (IBD) patients at six months using a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels. The results showed that proactive TDM was associated with a high persistence rate of 82.9% and favorable remission rates at six months.
Article
Gastroenterology & Hepatology
Silvio Danese, Elmer Schabel, Mark Andrew Ainsworth, Laurent Peyrin-Biroulet
Review
Gastroenterology & Hepatology
Camilla Frimor, Jens Kjeldsen, Mark Ainsworth
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2020)
Article
Gastroenterology & Hepatology
Sine Buhl, Maria Dorn-Rasmussen, Jorn Brynskov, Mark A. Ainsworth, Klaus Bendtzen, Pia Helene Klausen, Nils Bolstad, David J. Warren, Casper Steenholdt
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2020)
Article
Gastroenterology & Hepatology
Ana-Marija Grisic, Maria Dorn-Rasmussen, Bella Ungar, Jorn Brynskov, Johan F. K. F. Ilvemark, Nils Bolstad, David J. Warren, Mark A. Ainsworth, Wilhelm Huisinga, Shomron Ben-Horin, Charlotte Kloft, Casper Steenholdt
Summary: Infliximab clearance decreases significantly in the second and third trimesters of pregnancy, leading to increasing maternal infliximab concentrations in any given regimen. Maternal infliximab levels may be maintained as constant in a de-intensified regimen by therapeutic drug monitoring guidance in inflammatory bowel disease.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Medical Laboratory Technology
Maria Dorn-Rasmussen, Sine Buhl, Jorn Brynskov, Jakob T. Bay, Nils Bolstad, Tobias W. Klausen, David J. Warren, Mark A. Ainsworth, Casper Steenholdt
Summary: This study aimed to evaluate the relationship between IFX concentration and clinical and biochemical remission in inflammatory bowel disease, in order to implement therapeutic drug monitoring strategies. The results showed that an IFX concentration of 4.5 mcg/mL was associated with remission throughout the first year. Anti-IFX Abs were associated with low IFX levels and treatment failure.
THERAPEUTIC DRUG MONITORING
(2022)
Article
Gastroenterology & Hepatology
Katrine Risager Christensen, Casper Steenholdt, Sine Buhl, Jorn Brynskov, Mark Andrew Ainsworth
Summary: Patients and physicians both considered blood samples, stool samples, endoscopies, and MRI to be relevant aspects of monitoring the disease, but patients found collecting stool samples and undergoing endoscopies unpleasant. Physicians deemed blood samples, medical consultations, fecal calprotectin, endoscopy, and MRI as important aspects of IBD monitoring, but only considered endoscopies and MRI relevant in case of clinical signs of relapse. Adherence to using blood samples and disease activity indices was high (92%), while adherence to using fecal calprotectin (38%), therapeutic drug monitoring (38%), and endoscopies (32%) was low.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Katrine Risager Christensen, Mark Andrew Ainsworth, Casper Steenholdt, Sine Buhl, Marie Skougaard, Jorn Brynskov, Tanja Schjodt Jorgensen, Lars Erik Kristensen
Summary: This study aimed to explore the underlying causes of fatigue in patients with inflammatory bowel disease (IBD) receiving biologic therapy. Through principal component analysis, the study found that fatigue was mainly associated with the chronic nature of the disease, disease activity, and nutritional deficiencies.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Katrine Risager Christensen, Mark Andrew Ainsworth, Marie Skougaard, Casper Steenholdt, Sine Buhl, Jorn Brynskov, Lars Erik Kristensen, Tanja Schjodt Jorgensen
Summary: In this study, patients identified fatigue and stool frequency as the most important symptoms impacting their daily lives. However, when investigating the disease burden in a broader perspective beyond classic IBD symptoms, patients identified concepts with focus on emotional health to be most important.
BMJ OPEN GASTROENTEROLOGY
(2022)
Editorial Material
Gastroenterology & Hepatology
Mark A. Ainsworth
INFLAMMATORY BOWEL DISEASES
(2022)
Meeting Abstract
Gastroenterology & Hepatology
K. Risager Christensen, C. Steenholdt, M. Skougaard, M. A. Ainsworth, J. Brynskov, S. Buhl, L. E. Kristensen, T. Schjodt Jorgensen
JOURNAL OF CROHNS & COLITIS
(2021)
Meeting Abstract
Gastroenterology & Hepatology
K. Risager Christensen, C. Steenholdt, S. Buhl, M. Skougaard, J. Brynskov, M. A. Ainsworth, T. Schjodt Jorgensen, L. E. Kristensen
JOURNAL OF CROHNS & COLITIS
(2021)
Meeting Abstract
Gastroenterology & Hepatology
Sine Buhl, Casper Steenholdt, Jorn Brynskov, Katrine R. Christensen, Maria Dorn-Rasmussen, Ole O. Thomsen, Klaus Bendtzen, Tobias W. Klausen, Jens F. Dahlerup, Niels Thorsgaard, Jorgen Jahnsen, Akbar Molazahi, Natalia Pedersen, Jens Kjeldsen, Sven Almer, Eva E. Dahl, Ida Vind, Annett G. Cannon, Jan Marsal, Taina Sipponen, Jorgen Steen Agnholt, Hendrika A. Kievit, Synnove L. Aure, Lars Martinsen, Svetlana Meisner, Jane Moeller, Mark A. Ainsworth
Meeting Abstract
Gastroenterology & Hepatology
Ana-Marija Grisic, Maria Rasmussen, Bella Ungar, Johan F. Ilvemark, Wilhelm Huisinga, Nils Bolstad, David J. Warren, Shomron Ben-Horin, Mark A. Ainsworth, Jorn Brynskov, Charlotte Kloft, Casper Steenholdt
Meeting Abstract
Gastroenterology & Hepatology
Katrine R. Christensen, Casper Steenholdt, Sine Buhl, Jorn Brynskov, Mark A. Ainsworth
Meeting Abstract
Gastroenterology & Hepatology
K. Risager Christensen, C. Steenholdt, S. Buhl Naess-Schmidt, J. Brynskov, M. A. Ainsworth
JOURNAL OF CROHNS & COLITIS
(2019)